Table 1.
Comparison of clinicopathological features and treatment outcomes
| Overall | Early BCR | Intermediate BCR | Late BCR | Very late BCR | All BCR | p Value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. sample size (%)* | 10,609 | 1,297 | (12.2) | 280 | (2.6) | 82 | (0.8) | 25 | (0.2) | 1,684 | (15.9) | Not applicable | |
| Median age at RP (range) | 59.0 (33.0–81.0) | 59.0 (38.0–75.0) | 60.0 (44.0–73.0) | 60.0 (44.0–69.0) | 62.0 (51.0–70.0) | 60.0 (38.0–75.0) | 0.438 | ||||||
| No. African American (%) | 789 | (7.5) | 120 | (9.3) | 22 | (7.9) | 3 | (3.7) | 0 | (0.0) | 145 | (8.6) | 0.119 |
| No. yr of RP (%): | |||||||||||||
| Before 1989 | 683 | (6.4) | 170 | (13.1) | 62 | (22.1) | 29 | (35.4) | 19 | (76.0) | 280 | (16.6) | <0.0001 |
| 1989–1991 | 539 | (5.1) | 94 | (7.2) | 43 | (15.4) | 18 | (21.9) | 6 | (24.0) | 161 | (9.6) | |
| 1992–2009 | 9,387 | (88.5) | 1,033 | (79.7) | 175 | (62.5) | 35 | (42.7) | 0 | (0.0) | 1,243 | (73.8) | |
| Median PSA (range) | 5.7 (0.1–151.0) | 8.6 (0.1–151.0) | 8.0 (0.1–116.0) | 6.6 (0.9–38.0) | 8.2 (0.7–31.4) | 8.4 (0.1–151.0) | 0.003 | ||||||
| No. biopsy Gleason 7 or greater (%) | 2,536 | (24.0) | 726 | (56.7) | 102 | (36.8) | 20 | (24.4) | 6 | (25.0) | 854 | (51.3) | <0.0001 |
| No. clinical stage T2+ (%) | 3,914 | (37.2) | 774 | (60.3) | 186 | (66.9) | 64 | (79.0) | 22 | (88.0) | 1,046 | (62.8) | <0.0001 |
| No. pathological stage (%): | |||||||||||||
| Organ confined | 6,696 | (63.3) | 215 | (16.7) | 62 | (22.4) | 22 | (27.2) | 6 | (24.0) | 305 | (18.2) | |
| Extracapsular extension | 3,099 | (29.3) | 597 | (46.2) | 165 | (59.5) | 48 | (59.2) | 17 | (68.0) | 827 | (49.4) | <0.0001 |
| Seminal vesicle invasion | 449 | (4.2) | 229 | (17.7) | 26 | (9.4) | 5 | (6.2) | 2 | (8.0) | 262 | (15.7) | |
| Lymph node metastases | 333 | (3.2) | 250 | (19.4) | 24 | (8.7) | 6 | (7.4) | 0 | (0.0) | 280 | (16.7) | |
| No. pos surgical margins (%) | 1,512 | (14.3) | 518 | (40.2) | 79 | (28.2) | 22 | (26.8) | 7 | (28.0) | 626 | (37.3) | 0.0003 |
| No. salvage therapy after BCR (%) | 776 | (46.1) | 599 | (46.2) | 136 | (48.6) | 32 | (39.0) | 9 | (36.0) | 776 | (46.1) | 0.338 |
| No. local recurrence (%) | 249 | (3.3) | 201 | (20.3) | 35 | (15.4) | 5 | (6.8) | 6 | (24.0) | 247 | (18.8) | † |
| No. metastasis (%) | 464 | (4.7) | 416 | (33.7) | 42 | (15.6) | 4 | (5.2) | 2 | (8.0) | 464 | (28.9) | † |
| No. prostate Ca death (%) | 265 | (2.5) | 250 | (19.3) | 14 | (5.0) | 0 | (0.0) | 1 | (4.0) | 265 | (15.7) | † |
*
Due to missing data for some variables, the denominator in some cells may not equal the column total.
†
Comparison of crude proportions not performed due to differences in followup. See figure for Kaplan-Meier metastasis-free and cancer specific survival curves.